Polyfluorene‐based oligomers and polymers (PFs) have been studied intensively as active materials for organic optoelectronic devices. In this review, the optimization of the opto‐electronic property and device efficiency of polyfluorenes in the field of light‐emitting diodes (LEDs) and photovoltaic cells (PVs) by tuning structure and morphology are summarized in terms of two typical modification techniques: copolymerization and blending. The relationships between molecular structures, thin film morphologies, opto‐electronic properties and device efficiencies are discussed, and some recent progress in LEDs and PVs is simultaneously reviewed. After the introduction, the basic knowledge of molecular structures and properties of polyfluorene homopolymers is presented as a background for a better understanding of their great potential for opto‐electronic applications. Immediately after this, three different opinions on the origin of low‐energy emission band at 520–540 nm in polyfluorene‐based LEDs are addressed. Rod–coil block copolymers and alternative copolymers are focused on in the next section, which are a vivid embodiment of controlling supramolecular structures and tailoring molecular structures, respectively. In particular, various supramolecular architectures induced by altering coil blocks are carefully discussed. Recent work that shows great improvement in opto‐electronic properties or device performance by blending or doping is also addressed. Additionally, the progress of understanding concerning the mechanisms of exciton dynamics is briefly referred to. Copyright © 2006 Society of Chemical Industry

Dihydromyricetin (DMY), a flavanonol compound found as the most abundant and bioactive constituent in vine tea (Ampelopsis grossedentata), possesses numerous biological activities. In the present study, an HPLC-MS/MS method for the determination of DMY in tissues, urine, and feces was developed and applied to the tissue distribution and excretion study after oral administration in rats, and the metabolic profile of DMY was further investigated using UPLC-QTOF-MS. The results indicated that DMY could be distributed rapidly in various tissues and highly in the gastrointestinal tract. The elimination of DMY occurred rapidly as well, and most unconverted forms were excreted in feces. A total of eight metabolites were identified in urine and feces, while metabolites were barely found in plasma. The predicted metabolic pathways including reduction, dehydroxylation, methylation, glucuronidation, and sulfation were proposed. The present findings may provide the theoretical basis for evaluating the biological activities of DMY and will be helpful for its future development and application.

Reliable methods for the determination of tryptophan and its metabolites are vital to the monitoring of biochemical states during the initiation and progression of cardiovascular disease. In the present study, a single-run liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous determination of tryptophan (Trp) and its metabolites, including kynurenine (Kyn), kynurenic acid (KA), xanthurenic acid (XA) and 5-hydroxytryptamine (5-HT), in human plasma. The plasma samples were prepared using a protein precipitation approach, and the chromatographic separation was performed by gradient elution on a C column within a total analysis time of 3.5 min. The calibration ranges were 40-20,000 ng/mL for Trp, 4-2000 ng/mL for Kyn, 0.2-100 ng/mL for KA, 0.4-200 ng/mL for XA and 1-500 ng/mL for 5-HT, and the precision and accuracy were acceptable. The evaluation of recovery and internal standard-normalized matrix effect proved that the sample preparation approach was effective and the matrix effect could be negligible. The newly developed method was successfully applied to the analysis of plasma samples from healthy individuals and myocardial infarction patients. The findings suggested that the plasma concentrations of Trp, Kyn, 5-HT as well as the concentration ratios of Kyn/Trp and Trp/5-HT might serve as biomarkers for the monitoring of acute myocardial infarction.